136 related articles for article (PubMed ID: 30277120)
1. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor
Andersen MD; Kamper P; d'Amore A; Clausen M; Bentzen H; d'Amore F
Leuk Lymphoma; 2019 Apr; 60(4):927-933. PubMed ID: 30277120
[TBL] [Abstract][Full Text] [Related]
2. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
[TBL] [Abstract][Full Text] [Related]
3. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
Sun HL; Atenafu EG; Tsang R; Kukreti V; Marras TK; Crump M; Kuruvilla J
Leuk Lymphoma; 2017 Nov; 58(11):2607-2614. PubMed ID: 28504035
[TBL] [Abstract][Full Text] [Related]
4. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
Taparra K; Liu H; Polley MY; Ristow K; Habermann TM; Ansell SM
Leuk Lymphoma; 2020 Feb; 61(2):298-308. PubMed ID: 31517559
[TBL] [Abstract][Full Text] [Related]
5. Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.
Al-Jizani WA; Al-Mansour MM; Al-Fayea TM; Shafi RU; Kazkaz GA; Bayer AM; Al-Foheidi ME; Ibrahim EM
Future Oncol; 2015; 11(15):2149-57. PubMed ID: 26235180
[TBL] [Abstract][Full Text] [Related]
6. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?
Abou Yehia Z; Mikhaeel GN; Smith G; Pinnix CC; Milgrom SA; Tang C; Jiang W; Fanale MA; Oki Y; Shank JH; Horace T; Reddy J; Akhtari M; Gunther JR; Suki T; Allen PK; Turner S; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):951-958. PubMed ID: 27742539
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
Graczyk J; Cheung MC; Buckstein R; Chan K
Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
[TBL] [Abstract][Full Text] [Related]
10. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
[TBL] [Abstract][Full Text] [Related]
11. Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma.
Thomas TS; Luo S; Reagan PM; Keller JW; Sanfilippo KM; Carson KR
J Geriatr Oncol; 2020 Jan; 11(1):69-74. PubMed ID: 31668826
[TBL] [Abstract][Full Text] [Related]
12. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
Ho P; Sherman P; Grigg A
Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
[TBL] [Abstract][Full Text] [Related]
13. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
Ahmed BM; Al-Zakwani IS
J Oncol Pharm Pract; 2013 Mar; 19(1):3-7. PubMed ID: 22504168
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
Cheung MC; Prica A; Graczyk J; Buckstein R; Chan KK
Leuk Lymphoma; 2016 Aug; 57(8):1865-75. PubMed ID: 26758765
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
Saxman SB; Nichols CR; Einhorn LH
Chest; 1997 Mar; 111(3):657-60. PubMed ID: 9118704
[TBL] [Abstract][Full Text] [Related]
17. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
18. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
Azoulay E; Herigault S; Levame M; Brochard L; Schlemmer B; Harf A; Delclaux C
Crit Care Med; 2003 May; 31(5):1442-8. PubMed ID: 12771616
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.
Ngeow J; Tan IB; Kanesvaran R; Tan HC; Tao M; Quek R; Lim ST
Ann Hematol; 2011 Jan; 90(1):67-72. PubMed ID: 20676640
[TBL] [Abstract][Full Text] [Related]
20. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.
Lei KI; Leung WT; Johnson PJ
Br J Cancer; 1994 Nov; 70(5):1009-13. PubMed ID: 7524599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
